Moreover, deltarasin does not inhibit the growth of cells transformed with the oncogenic mutant B-Raf or the overexpressed epidermal growth factor receptor (EGFR) (Klein et al., 2019), suggesting that PDE6δ inhibitors are effective against K-Ras–dependent cancer cells. Here, BRAF is linked to cancer.